The CTL-DC#1 line recognizes predicted HLA-A2 binding peptides derived from the p53-dependent protein MDM-2. Predicted HLA-A2 binding peptides derived from MDM-2 (see Table 3) and the known p53_264-272 epitope were evaluated for their ability to activate CD8+ T cells isolated from the CTL-DC#1 line when presented by the HLA-A2+ T2 cell line in IFN-gamma ELISPOT assays. The anti-HLA-A2 mAb MA2.1 was added (5 µg/well) to replicate sets of wells to validate the HLA-A2-restricted nature of peptide recognition by the CTLs. Assays were performed in triplicate and spots were counted using a Zeiss autoimager. The data are reported as the mean ± SD for one representative analysis of 3 independent assays performed.